“It is very gratifying to see the impact that we are having in the field of diagnostics. I have just returned from the ASHI event, a major transplantation conference in the US, and it is clear that many things are going our way at the moment. This applies not only to transplantation, but also to our other areas of operation.
Several milestones were reached during the quarter. We moved all our production and development to our now approved new premises. A number of product registrations were granted around the world during the quarter, while the development of new products is continuing unabated.”
Fredrik Alpsten, CEO, Devyser
The quarter from July to
- Net sales amounted to
SEK 48.7 million (46.7), corresponding to a 4.4 percent increase. Adjusted for exchange rate fluctuations, net sales increased by 7.2 percent. - Gross profit totaled
SEK 35.2 million (39.6), corresponding to a gross margin of 72.3 percent (85.0). - Operating profit (EBIT) amounted to
SEK -23.7 million (-7.8). - Profit after tax totaled
SEK -23.2 million (-6.0). - Earnings per share before and after dilution amounted to
SEK -1.41 (-0.37). - Cash flow from operating activities stood at
SEK -12.9 million (-13.9).
The period from January to
- Net sales amounted to
SEK 152.7 million (123.9), corresponding to a 23.3 percent increase. Adjusted for exchange rate fluctuations, net sales increased by 23.7 percent. - Gross profit totaled
SEK 118.5 million (104.8), corresponding to a gross margin of 77.6 percent (84.6). - Operating profit (EBIT) amounted to
SEK -59.0 million (-40.4). - Profit after tax totaled
SEK -58.3 million (-40.5). - Earnings per share before and after dilution amounted to
SEK -3.56 (-2.51). - Cash flow from operating activities stood at
SEK -45.4 million (-56.0).
Important events during the quarter
Tender won in
In July, Devyser won a tender with its NGS test for cystic fibrosis, Devyser CFTR. The contract with Policlinico Milano is for three years with the possibility of a one-year extension. The estimated order value is up to
The share and new share issues
Three new share issues were carried out during the quarter in connection with the exercising of employee stock options. The issues raised
Important events after the end of the quarter
Devyser presented new innovations and research
Devyser is continuing to invest in product development. At ASHI 2024, the foremost transplantation conference in the US, held at the end of October, six posters and one abstract were presented showcasing new, innovative Devyser products and the clinical results achieved from using them. These showed, among other things, the advantages offered by our products compared with the competition.
Devyser will terminate its liquidity guarantee agreement
In October, Devyser announced that its liquidity guarantee agreement with
Expanded collaboration with
In addition to the commercial terms of the cooperation agreement with
Chinese regulatory approval for Devyser Compact
Devyser has achieved a significant regulatory milestone with its first market registration from China’s
Presentation
The report will be presented at an audiocast at
This report and previous financial reports are available on the company’s webpage https://investors.devyser.com/en/reports-presentations.
© Modular Finance, source